About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Covid-19 Vaccine Response in Elderly Subjects | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDNCT04760704

Covid-19 Vaccine Response in Elderly Subjects

The objective of this research is to assess the amplitude and quality of the vaccine response against SARS-CoV-2, defined here by its characteristics established at 3 months, and its persistence over ...

Lead sponsor: University Hospital, Lille•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

University Hospital, Lille

Age

40 - No limit years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Target population.
•Elderly persons \> 65 years old residing in an institution for the elderly or in a long-term care unit for whom an anti-SARS-CoV-2 vaccination is indicated as recommended by French Health Authority (HAS)
•Male or female resident in an institution for the elderly or in a long-term care unit
•For whom consent has been obtained prior to any SARS-CoV-2 vaccination (or from the legal guardian/curator) by COMIRNATY®.
•Having consented to participate in the study, and willing to comply with all study procedures and its duration
•Socially insured patient
•Control population
•Health and medico-social sector professionals aged between 40 and 65 years old for whom a COMIRNATY® anti-SARS-CoV-2 vaccination is indicated as recommended by the HAS.
•Male or female between 40 and 65 years of age included
•For whom consent has been obtained prior to any COMIRNATY® SARS-CoV-2 vaccination.
•Having consented to participate in the study, and willing to comply with all study procedures and its duration
•Socially insured subject

Exclusion Criteria

•Progressive infectious pathology
•Progressive neoplastic pathology (or remission of \< 5 years)
•Treatment with long-term corticosteroids or immunosuppressants
•Refuse of consent to vaccination or study

Related studies

COVID-19 Vaccines Safety Tracking (CoVaST)

NCT04834869 · Adverse Reaction to Vaccine, COVID19 Vaccine

COMPLETEDPhase 2

PTX-COVID19-B, an mRNA Humoral Vaccine, Intended for Prevention of COVID-19 in a General Population. This Study is Designed to Demonstrate the Safety, Tolerability, and Immunogenicity of PTX-COVID19-B in Comparison to the Pfizer-BioNTech COVID-19 Vaccine.

NCT05175742 · Covid19 Vaccine

Immunogenicity of COVID-19 Vaccine in Patients With Inflammatory Bowel Disease

NCT04818892 · IBD, Covid19 Vaccine

WITHDRAWNPhase 3

IntraDermal Versus Intramuscular Comirnaty® Efficacy Study

NCT05029245 · Covid19 Vaccine, Covid19

COMPLETEDPhase 2

A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Adolescents

NCT04951388 · Covid19 Vaccine

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: December 26, 2025Terms

Trial snapshot

StatusCOMPLETED

Phase—

Enrollment264

Start dateFeb 2021

Last updatedDec 26, 2025

Condition

Covid19 Vaccine

Locations shown

CHU lille

Lille

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 26, 2025Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions